Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more
Valbiotis SAS (ALVAL) - Total Liabilities
Latest total liabilities as of June 2025: €8.14 Million EUR
Based on the latest financial reports, Valbiotis SAS (ALVAL) has total liabilities worth €8.14 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Valbiotis SAS - Total Liabilities Trend (2015–2024)
This chart illustrates how Valbiotis SAS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Valbiotis SAS Competitors by Total Liabilities
The table below lists competitors of Valbiotis SAS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Generation Mining Limited
OTCQB:GENMF
|
USA | $64.63 Million |
|
Ideal Power Inc
NASDAQ:IPWR
|
USA | $2.15 Million |
|
Novo Resources Corp
OTCQB:NSRPF
|
USA | $16.43 Million |
|
Yooshin Engineering Corporation
KQ:054930
|
Korea | ₩170.85 Billion |
|
Wiable Corp
KQ:065530
|
Korea | ₩50.28 Billion |
|
Maeil Holdings Co. Ltd
KQ:005990
|
Korea | ₩548.37 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Valbiotis SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.06 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valbiotis SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valbiotis SAS (2015–2024)
The table below shows the annual total liabilities of Valbiotis SAS from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.24 Million | -32.62% |
| 2023-12-31 | €13.71 Million | -1.08% |
| 2022-12-31 | €13.86 Million | -2.72% |
| 2021-12-31 | €14.25 Million | +2.29% |
| 2020-12-31 | €13.93 Million | +104.63% |
| 2019-12-31 | €6.81 Million | +51.35% |
| 2018-12-31 | €4.50 Million | +76.15% |
| 2017-12-31 | €2.55 Million | +103.43% |
| 2016-12-31 | €1.25 Million | +16.31% |
| 2015-12-31 | €1.08 Million | -- |